Overview

Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects

Status:
Completed
Trial end date:
2017-06-20
Target enrollment:
Participant gender:
Summary
Study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic effect of JTE-451 administered for 4 weeks in subjects with active plaque psoriasis.
Phase:
Phase 1
Details
Lead Sponsor:
Akros Pharma Inc.